Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Pharmacopsychiatry|December 17, 2003
Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disordersJ Kirchheiner, L Bertilsson, H Bruus, et al.
The Pharmacogenomics Journal|May 17, 2006
A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatmentJ Kirchheiner, K Nickchen, J Sasse, et al.
Der Internist|November 28, 2009
[Interactions with antiretroviral drugs]A Ceschi, I Curkovic, J Kirchheiner, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 4, 2005
Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivoM Ufer, B Kammerer, R Kahlich, et al.
Molecular Psychiatry|March 24, 2004
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseJ Kirchheiner, K Nickchen, M Bauer, et al.
Pharmacopsychiatry|December 17, 2003
Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imagingM Bauer, E D London, D H Silverman, et al.
British Journal of Clinical Pharmacology|June 21, 2005
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agentsA Holstein, A Plaschke, M Ptak, et al.
The Pharmacogenomics Journal|September 14, 2006
Genetic variation at the CYP2C locus and its association with torsemide biotransformationS V Vormfelde, M Schirmer, M R Toliat, et al.
Ernst Schering Research Foundation Workshop|November 23, 2006
Genotype and phenotype relationship in drug metabolismI Roots, G Laschinski, F Arjomand-Nahad, et al.
Clinical Pharmacology and Therapeutics|April 17, 2009
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteersS V Vormfelde, J Brockmöller, S Bauer, et al.
Pageof 3